Clinical Research Directory
Browse clinical research sites, groups, and studies.
PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers
Sponsor: JW Pharmaceutical
Summary
A Phase 1 Study to evaluate the safety, PK/PD, drug-drug interaction(DDI) of Epaminurad and Naproxen in Healthy Volunteers
Official title: A Phase 1 Study to Evaluate the Safety and PK/PD Drug-drug Interaction Between Epaminurad and Naproxen or to Assess the Safety and Multiple-Dose PK/PD Characteristics of Epaminurad in Healthy Volunteers
Key Details
Gender
All
Age Range
19 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2024-06-03
Completion Date
2026-01
Last Updated
2025-09-09
Healthy Volunteers
Yes
Conditions
Interventions
Epaminurad, Naproxen
Period 1: Epaminurad 6mg -\> Epaminurad 9mg -\> Epaminurad 9mg +Naproxen Period 2: Naproxen
Epaminurad
Epaminurad
Epaminurad placebo
Epaminurad placebo
Locations (1)
Seoul National University Hospital
Seoul, South Korea